Gemelli Biotech is a specialty biotechnology company founded with the mission to support the discovery of novel diagnostics and therapeutics for the human microbiome. The company's vision is to create a thriving global family of healthy individuals by unlocking the potential of the microbiome. Gemelli Biotech offers non-invasive precision diagnostics aimed at detecting scientifically validated biomarkers to optimally treat gastrointestinal diseases, including SIBO (Small Intestinal Bacterial Overgrowth), IMO (Intestinal Methanogen Overgrowth), excess hydrogen sulfide, and post-infectious IBS (Irritable Bowel Syndrome).

Notable affiliated individuals and investors include leading experts in microbiome research and biotechnology. The company has achieved significant milestones in developing and commercializing non-invasive diagnostic tests that have improved the accuracy and ease of diagnosing complex GI conditions. Gemelli Biotech's impact is evident in its contribution to advancing precision medicine, providing clinicians with tools to better understand and treat gastrointestinal diseases, ultimately improving patient outcomes and quality of life.